IT1191674B
(it)
*
|
1986-03-07 |
1988-03-23 |
Eurand Spa |
Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
|
US4792452A
(en)
*
|
1987-07-28 |
1988-12-20 |
E. R. Squibb & Sons, Inc. |
Controlled release formulation
|
US4994276A
(en)
*
|
1988-09-19 |
1991-02-19 |
Edward Mendell Co., Inc. |
Directly compressible sustained release excipient
|
US5128143A
(en)
*
|
1988-09-19 |
1992-07-07 |
Edward Mendell Co., Inc. |
Sustained release excipient and tablet formulation
|
US5169639A
(en)
*
|
1988-09-19 |
1992-12-08 |
Edward Mendell Co., Inc. |
Controlled release verapamil tablets
|
US5009895A
(en)
*
|
1990-02-02 |
1991-04-23 |
Merck & Co., Inc. |
Sustained release with high and low viscosity HPMC
|
IT1250483B
(it)
*
|
1990-08-30 |
1995-04-07 |
Eurand Int |
Sistema di ritardo a matrice multipla
|
DE4140183C2
(de)
*
|
1991-12-05 |
1995-12-21 |
Alfatec Pharma Gmbh |
Retardform für ein Flurbiprofen enthaltendes Arzneimittel
|
DE4140172C2
(de)
*
|
1991-12-05 |
1995-12-21 |
Alfatec Pharma Gmbh |
Retardform für ein Ibuprofen enthaltendes Arzneimittel
|
DE4140179C2
(de)
*
|
1991-12-05 |
1995-12-21 |
Alfatec Pharma Gmbh |
Akutform für ein Ibuprofen enthaltendes Arzneimittel
|
DE4140192C2
(de)
*
|
1991-12-05 |
1996-02-29 |
Alfatec Pharma Gmbh |
Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
|
DE4140184C2
(de)
*
|
1991-12-05 |
1995-12-21 |
Alfatec Pharma Gmbh |
Akutform für ein Flurbiprofen enthaltendes Arzneimittel
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5292534A
(en)
*
|
1992-03-25 |
1994-03-08 |
Valentine Enterprises, Inc. |
Sustained release composition and method utilizing xanthan gum and an active ingredient
|
US5472711A
(en)
*
|
1992-07-30 |
1995-12-05 |
Edward Mendell Co., Inc. |
Agglomerated hydrophilic complexes with multi-phasic release characteristics
|
AU5745394A
(en)
*
|
1992-12-30 |
1994-08-15 |
Fmc Corporation |
Readily available konjac glucomannan sustained release excipient
|
US5662933A
(en)
|
1993-09-09 |
1997-09-02 |
Edward Mendell Co., Inc. |
Controlled release formulation (albuterol)
|
US5455046A
(en)
*
|
1993-09-09 |
1995-10-03 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
US6726930B1
(en)
*
|
1993-09-09 |
2004-04-27 |
Penwest Pharmaceuticals Co. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
US5773025A
(en)
*
|
1993-09-09 |
1998-06-30 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems--amorphous drugs
|
US5464067A
(en)
*
|
1994-01-11 |
1995-11-07 |
Dulak; Joseph O. |
Golf marker cleaner and grass remover
|
US6395303B1
(en)
*
|
1996-06-10 |
2002-05-28 |
Edward Mendell Co., Inc. |
Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
|
FR2729857B1
(fr)
*
|
1995-01-27 |
1997-04-04 |
Rhone Poulenc Chimie |
Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire
|
WO1997026865A1
(en)
*
|
1996-01-29 |
1997-07-31 |
Edward Mendell Co., Inc. |
Sustained release excipient
|
ES2322405T3
(es)
*
|
1996-07-08 |
2009-06-19 |
Penwest Pharmaceuticals Co. |
Matriz de liberacion controlada para farmacos insolubles en dosis elevadas.
|
IN186245B
(xx)
|
1997-09-19 |
2001-07-14 |
Ranbaxy Lab Ltd |
|
US6607751B1
(en)
*
|
1997-10-10 |
2003-08-19 |
Intellipharamaceutics Corp. |
Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
|
US6056977A
(en)
|
1997-10-15 |
2000-05-02 |
Edward Mendell Co., Inc. |
Once-a-day controlled release sulfonylurea formulation
|
US20030153623A1
(en)
*
|
1998-07-22 |
2003-08-14 |
Yamanouchi Pharmaceutical Co., Ltd. |
Solid preparation containing sparingly soluble NSAIDs
|
GB9816723D0
(en)
*
|
1998-08-01 |
1998-09-30 |
Boots Co Plc |
Therapeutic agents
|
EP1137403B1
(en)
|
1998-12-11 |
2009-03-11 |
Nostrum Pharmaceuticals, Inc. |
Sustained release tablet containing hydrocolloid and cellulose ether
|
US7250176B1
(en)
*
|
1999-04-13 |
2007-07-31 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection
|
US6294199B1
(en)
|
1999-04-13 |
2001-09-25 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising administering amoxycillin
|
DE60038536T2
(de)
*
|
1999-09-30 |
2009-06-10 |
Penwest Pharmaceuticals Co. |
Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
|
US7235258B1
(en)
*
|
1999-10-19 |
2007-06-26 |
Nps Pharmaceuticals, Inc. |
Sustained-release formulations for treating CNS-mediated disorders
|
CA2406383A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Mayo Foundation For Medical Education And Research |
A.beta.42 lowering agents
|
AU2001284561A2
(en)
*
|
2000-08-22 |
2002-03-04 |
Agresearch Limited |
A release composition and method of preparation
|
AR030575A1
(es)
*
|
2000-08-22 |
2003-08-27 |
Agres Ltd |
Aglutinante biologico termoestable y metodo de preparacion
|
WO2002030392A2
(en)
|
2000-10-12 |
2002-04-18 |
Beecham Pharmaceuticals (Pte) Limited |
Formulation containing amoxicillin
|
US6756057B2
(en)
|
2000-10-12 |
2004-06-29 |
Beecham Pharmaceuticals (Pte) Limited |
Amoxicillin and potassium clavulanate dosage form
|
AU2001227030A1
(en)
*
|
2000-11-22 |
2002-06-03 |
Lupin Laboratories Limited |
Pharmaceutical composition for controlled release of an active ingredient
|
US20030070584A1
(en)
*
|
2001-05-15 |
2003-04-17 |
Cynthia Gulian |
Dip coating compositions containing cellulose ethers
|
US20030072731A1
(en)
*
|
2001-05-15 |
2003-04-17 |
Cynthia Gulian |
Dip coating compositions containing starch or dextrin
|
AU4061702A
(en)
*
|
2001-05-15 |
2003-04-03 |
Mcneil-Ppc, Inc. |
Dip coating compositions containing starch or dextrin
|
WO2003004030A1
(en)
*
|
2001-07-06 |
2003-01-16 |
Endo Pharmaceuticals, Inc. |
Oxymorphone controlled release formulations
|
US8329216B2
(en)
*
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
US6705028B2
(en)
*
|
2001-09-12 |
2004-03-16 |
Honda Giken Kogyo Kabushiki Kaisha |
Self-propelled snowplow vehicle
|
EP1429730A4
(en)
*
|
2001-09-26 |
2010-06-16 |
Penwest Pharmaceuticals Compan |
OPIOID FORMULATIONS WITH REDUCED ABUSE POTENTIAL
|
US8309118B2
(en)
*
|
2001-09-28 |
2012-11-13 |
Mcneil-Ppc, Inc. |
Film forming compositions containing sucralose
|
AU2002224011B2
(en)
*
|
2001-11-19 |
2008-05-01 |
Lupin Limited |
A pharmaceutical composition for controlled release of a beta-lactam antibiotic
|
CN1642532A
(zh)
*
|
2002-03-22 |
2005-07-20 |
西拉格股份公司 |
曲马多缓释制剂
|
US7429619B2
(en)
*
|
2002-08-02 |
2008-09-30 |
Mcneil Consumer Healthcare |
Polyacrylic film forming compositions
|
KR20050075408A
(ko)
*
|
2002-12-13 |
2005-07-20 |
시락 아게 |
트라마돌 및 토피라메이트를 포함하는 방출 조절형 제제
|
US20060222713A1
(en)
*
|
2002-12-16 |
2006-10-05 |
Deepak Murpani |
Extended release pharmaceutical composition of phenytoin sodium
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
|
CA2529984C
(en)
|
2003-06-26 |
2012-09-25 |
Isa Odidi |
Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
|
EP1651195A4
(en)
*
|
2003-07-11 |
2007-10-03 |
Myriad Genetics Inc |
PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
|
ATE390122T1
(de)
*
|
2003-09-01 |
2008-04-15 |
Jpm The Jordanian Pharmaceutic |
Universelle zusammensetzung zur kontrollierten wirkstofffreigabe enthaltend xanthangummi und natriumalginat
|
US20050202079A1
(en)
*
|
2004-03-15 |
2005-09-15 |
Mylan Pharmaceuticals Inc. |
Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
|
ES2244324B1
(es)
*
|
2004-03-25 |
2006-11-16 |
Ferrer Internacional, S.A. |
Composiciones diureticas de liberacion prolongada.
|
US20070293538A1
(en)
*
|
2004-04-13 |
2007-12-20 |
Myriad Genetics, Incorporated |
Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
|
AU2005241023A1
(en)
*
|
2004-04-29 |
2005-11-17 |
Keystone Retaining Wall Systems, Inc. |
Veneers for walls, retaining walls and the like
|
US8394409B2
(en)
*
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
CA2618985A1
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
AU2005280058B2
(en)
*
|
2004-08-25 |
2010-09-02 |
Essentialis, Inc. |
Pharmaceutical formulations of potassium ATP channel openers and uses thereof
|
US20070077297A1
(en)
|
2004-09-30 |
2007-04-05 |
Scolr Pharma, Inc. |
Modified release ibuprofen dosage form
|
CA2584469A1
(en)
*
|
2004-10-26 |
2006-05-04 |
Mcneil-Ppc, Inc. |
Burst-release polymer composition and dosage forms comprising the same
|
WO2006123357A2
(en)
*
|
2005-02-22 |
2006-11-23 |
Sun Pharmaceutical Industries Limited |
Oral controlled release composition containing levetiracetam
|
US9757384B2
(en)
|
2005-04-06 |
2017-09-12 |
Essentialis, Inc. |
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
|
WO2007014124A2
(en)
*
|
2005-07-22 |
2007-02-01 |
Myriad Genetics, Inc. |
High drug load formulations and dosage forms
|
US20070036859A1
(en)
*
|
2005-08-11 |
2007-02-15 |
Perry Ronald L |
Sustained release antihistamine and decongestant composition
|
WO2007069874A1
(en)
*
|
2005-12-16 |
2007-06-21 |
Hanmi Pharm. Co., Ltd. |
Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
ES2374963T3
(es)
|
2006-01-05 |
2012-02-23 |
Essentialis, Inc. |
Sales de agentes de apertura del canal de potasio dependiente de atp y usos de las mismas.
|
US8309104B2
(en)
|
2006-03-02 |
2012-11-13 |
Watson Pharmaceuticals, Inc. |
Oral controlled release formulation for sedative and hypnotic agents
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
EP2007360B1
(en)
*
|
2006-04-03 |
2014-11-26 |
Isa Odidi |
Controlled release delivery device comprising an organosol coat
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
US7749537B2
(en)
*
|
2006-12-04 |
2010-07-06 |
Scolr Pharma, Inc. |
Method of forming a tablet
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
US20080318994A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
|
US20080318993A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
|
CA2692160A1
(en)
*
|
2007-07-02 |
2009-01-08 |
Essentialis, Inc. |
Salts of potassium atp channel openers and uses thereof
|
DE102007032662A1
(de)
*
|
2007-07-13 |
2009-01-22 |
Beiersdorf Ag |
Kosmetische oder dermatologische Zubereitungen enthaltend ein oder mehrere Apiogalacturonane oder einen oder mehrere Apiogalacturonane enthaltenden Extrakt aus Zostera marina und einen zusätzlichen Gehalt an einem oder mehreren Hydrokolloiden
|
WO2011102506A1
(ja)
*
|
2010-02-22 |
2011-08-25 |
第一三共株式会社 |
経口用徐放性固形製剤
|
WO2013095317A2
(en)
*
|
2011-12-23 |
2013-06-27 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Pharmaceutical formulations of flurbiprofen and glucosamin
|
WO2013100881A2
(en)
|
2011-12-27 |
2013-07-04 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Combined pharmaceutical formulation containing diacerein
|
EP2819675A4
(en)
|
2012-02-27 |
2015-07-22 |
Essentialis Inc |
SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF
|
WO2014007777A1
(en)
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Combined capsule formulations of nsaids
|
WO2014007778A1
(en)
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
COMBINED IMMEDIATE RELEASE FORMULATIONS OF NSAIDs
|
CA3210794A1
(en)
|
2014-11-14 |
2016-05-19 |
Essentialis, Inc. |
Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
|
CN108904451A
(zh)
*
|
2018-07-27 |
2018-11-30 |
广州柏赛罗药业有限公司 |
缓释制剂
|